5:45 PM
 | 
Mar 17, 2008
 |  BC Extra  |  Top Story

Dynavax's Heplisav on clinical hold

Dynavax (NASDAQ:DVAX) said FDA placed a clinical hold on Heplisav after an individual in the Phase III PHAST trial was diagnosed with Wegener's granulomatosis, a disease in which the blood vessels are inflamed. Dosing was complete in...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >